Compare GDRX & MPLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GDRX | MPLT |
|---|---|---|
| Founded | 2011 | 2018 |
| Country | United States | United States |
| Employees | 738 | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 868.9M | 772.7M |
| IPO Year | 2020 | 2025 |
| Metric | GDRX | MPLT |
|---|---|---|
| Price | $2.52 | $18.32 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 4 |
| Target Price | $4.78 | ★ $31.00 |
| AVG Volume (30 Days) | ★ 2.1M | 171.4K |
| Earning Date | 02-26-2026 | 02-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $800,651,000.00 | N/A |
| Revenue This Year | $2.30 | N/A |
| Revenue Next Year | $2.63 | N/A |
| P/E Ratio | $29.60 | ★ N/A |
| Revenue Growth | ★ 1.30 | N/A |
| 52 Week Low | $2.47 | $12.24 |
| 52 Week High | $5.81 | $21.55 |
| Indicator | GDRX | MPLT |
|---|---|---|
| Relative Strength Index (RSI) | 31.70 | N/A |
| Support Level | $2.47 | N/A |
| Resistance Level | $2.63 | N/A |
| Average True Range (ATR) | 0.11 | 0.00 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 11.23 | 0.00 |
GoodRx Holdings Inc is a consumer-focused digital healthcare platform that aims to lower the cost of healthcare in the United States. It operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and provides access to negotiated prices through codes that can be used to save money on prescriptions across the United States. GoodRx generates revenue from core business from pharmacy benefit managers (PBMs) that manage formularies and prescription transactions including establishing pricing between consumers and pharmacies. It also offers various healthcare products and services, including pharma manufacturer solutions, subscriptions, and telehealth services.
MapLight Therapeutics Inc is a biopharmaceutical company. The company is focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. The company is engaged in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. The product candidates of the company include ML-007C-MA, ML-004, ML-021, ML-009, and other pipeline products.